Test-retest repeatability of ADC in prostate using the multi b-Value VERDICT acquisition. Issue 162 (May 2023)

• Record Type: Journal Article
• Authors: Rogers, Harriet J.; Singh, Saurabh; Barnes, Anna; Obuchowski, Nancy A.; Margolis, Daniel J.; Malyarenko, Dariya I.; Chenevert, Thomas L.; Shukla-Dave, Amita; Boss, Michael A.; Punwani, Shonit
• Is Part Of: European journal of radiology. Issue 162(2023)
• Publication Date: 2023-05
• Subjects: Magnetic Resonance Imaging -- Prostate Cancer -- Diffusion Weighted Imaging -- Apparent Diffusion Coefficient -- Repeatability; ADC Apparent Diffusion Coefficient -- VERDICT Vascular Extracellular and Restricted Diffusion for Cytometry in Tumors -- PI-RADS Prostate Imaging Reporting and Data System -- ROI Region of Interest -- mpMRI Multiparametric MRI -- wSD Within-subject Standard Deviation -- TZ Transition Zone -- PZ Peripheral Zone -- DWI Diffusion Weighted Imaging; Medical radiology -- Periodicals; Radiology -- Periodicals; Radiologie médicale -- Périodiques; Medical radiology; Periodicals; 616.075705
• DOI: 10.1016/j.ejrad.2023.110782
• Languages: English
• ISSNs: 0720-048X

Abstract

Highlights: Prostate ADC repeatability has significant differences for varying b -value groups. ADC from b 0 b 1500 provides the least variability in prostate. wSD for normal PZ, TZ and prostate lesions do not increase with increasing ADC. ADC repeatability increases with larger ROI size in prostate. Abstract: Purpose: VERDICT (Vascular, Extracellular, Restricted Diffusion for Cytometry in Tumours) MRI is a multi b -value, variable diffusion time DWI sequence that allows generation of ADC maps from different b -value and diffusion time combinations. The aim was to assess precision of prostate ADC measurements from varying b -value combinations using VERDICT and determine which protocol provides the most repeatable ADC. Materials and Methods: Forty-one men (median age: 67.7 years) from a prior prospective VERDICT study (April 2016–October 2017) were analysed retrospectively. Men who were suspected of prostate cancer and scanned twice using VERDICT were included. ADC maps were formed using 5 b -value combinations and the within-subject standard deviations (wSD) were calculated per ADC map. Three anatomical locations were analysed per subject: normal TZ (transition zone), normal PZ (peripheral zone), and index lesions. Repeated measures ANOVAs showed which b -value range had the lowest wSD, Spearman correlation and generalized linear model regression analysis determined whether wSD was related to ADC magnitude and ROI size. Results: The mean lesion ADC for b 0 b 1500 had the lowest wSD in most zones (0.18–0.58x10 -4 mm 2 /s). The wSD was unaffected by ADC magnitude (Lesion: p = 0.064, TZ: p = 0.368, PZ: p = 0.072) and lesion Likert score ( p = 0.95). wSD showed a decrease with ROI size pooled over zones ( p = 0.019, adjusted regression coefficient = -1.6x10 -3, larger ROIs for TZ versus PZ versus lesions). ADC maps formed with a maximum b -value of 500 s/mm 2 had the largest wSDs (1.90–10.24x10 -4 mm 2 /s). Conclusion: ADC maps generated from b 0 b 1500 have better repeatability in normal TZ, normal PZ, and index lesions.